Literature DB >> 21261593

Molecular determinants of selective agonist and antagonist binding to the histamine H₄ receptor.

Enade P Istyastono1, Chris de Graaf, Iwan J P de Esch, Rob Leurs.   

Abstract

The deorphanization of the histamine H₄ receptor (H₄R) has led to a significant number of scientific publications and patent applications. Whereas some histamine H₁, H₂ and H₃ receptor ligands were found to have significant affinity for H₄R, several agonists and antagonists with high affinity for H₄R and selectivity over the other histamine receptors were successfully designed and synthesized. Moreover, site-directed mutation studies on H₄R have been performed and reveal detailed information on receptor-ligand interactions. This review will focus on the most important H₄R ligand scaffolds and their structure-activity relationships and selectivity over other histamine receptors and specific H₄R functional activity. Experimental data are used to construct and validate high resolution three-dimensional receptor-ligand models and, vice versa, in silico models are used to design and rationalize experimental studies to probe receptor-ligand interactions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21261593     DOI: 10.2174/1568026611109060661

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  2 in total

1.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.

Authors:  S Nijmeijer; H Engelhardt; S Schultes; A C van de Stolpe; V Lusink; C de Graaf; M Wijtmans; E E J Haaksma; I J P de Esch; K Stachurski; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.